(Q39812931)

14 September 2017

title

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience (English)

1 reference

14 September 2017

0 references

1 reference

Mark S Soloway

1

1 reference

14 September 2017

Cynthia T Soloway

2

1 reference

14 September 2017

Steve Williams

3

1 reference

14 September 2017

Rajinikanth Ayyathurai

4

1 reference

14 September 2017

Bruce Kava

5

1 reference

14 September 2017

Murugesan Manoharan

6

1 reference

14 September 2017

publication date

10 September 2007

1 reference

14 September 2017

1 reference

14 September 2017

volume

101

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

165-169

1 reference

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

The changing face of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Active surveillance: towards a new paradigm in the management of early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

Active surveillance with selective delayed intervention for favorable risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07190.X

10.1111/J.1464-410X.2007.07190.X

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference